Trial Profile
A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen alone in the treatment of patients with multidrug-resistant pulmonary tuberculosis
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Clofazimine (Primary)
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Sponsors Novartis
- 10 Jan 2017 This trial has been Discontinued in Latvia, according to European Clinical Trials Database.
- 10 Jan 2017 This trial has been Discontinued in Lithuania, according to European Clinical Trials Database.
- 10 Mar 2016 New trial record